Parkinson's Disease and Movement DisordersJoseph Jankovic, Eduardo Tolosa This edition features extensive updates on genetics, imaging and therapeutics of Parkinson disease. A bound-in "Video atlas of movement disorders" demonstrates the movement abnormalities and other disturbancies associated with Parkinson. Comprehensive text highlights recent advances in basic and clinical sciences related to movement disorders. For neurologists, psychiatrists, primary care physicians, and nurses. |
Contents
Neurophysiology of Motor Control and Movement | 7 |
Neurobehavioral Disorders Associated with Basal | 23 |
Role of the Ubiquitin | 33 |
Epidemiology of Movement Disorders | 50 |
Nonmotor Symptoms in Parkinsons Disease | 67 |
Disease | 77 |
Genetics of Parkinsons Disease | 93 |
Disease | 102 |
Neuropathology of Parkinsonian Disorders | 271 |
Mitochondria in Movement Disorders | 284 |
Differential Diagnosis | 298 |
Dystonic Disorders | 321 |
Treatment of Dystonia | 348 |
Tics and Tourettes Syndrome | 356 |
Myoclonus and Startle Syndromes | 376 |
Treatment of Myoclonus | 387 |
Pharmacological Management of Parkinsons | 110 |
Experimental Therapeutics of Parkinsons Disease | 146 |
Progressive Supranuclear Palsy | 161 |
Multiple System Atrophy | 175 |
Inherited and Sporadic Tauopathies | 203 |
Huntingtons Disease | 225 |
Chorea Ballism and Athetosis | 236 |
Neurodegeneration with Brain Iron | 246 |
DrugInduced Movement Disorders | 394 |
Movement Disorders in Children | 481 |
Rigidity and Spasticity | 504 |
Muscle Cramps Stiffness and Myalgia 514 47 DeepBrain Stimulation for Movement | 653 |
Assessment of Behavior in Parkinsonian Pierre Pollak Paul Krack | 687 |
| 703 | |
Other editions - View all
Common terms and phrases
a-synuclein abnormal activity alpha-synuclein amantadine Ann Neurol anticholinergics Arch Neurol associated ataxia autosomal basal ganglia behavior botulinum toxin brain caudate cause cell cerebellar chorea chromosome Clin clinical cognitive cortex cortical deficits degeneration dementia diagnosis dopamine agonists dose double-blind drugs dysfunction dyskinesias dystonic effect essential tremor factors focal function gene genetic Huntington's disease idiopathic impairment improvement increased inhibition inhibitors Jankovic L-dopa lesions levodopa Lewy bodies LRRK2 ment mitochondrial motor complications motor fluctuations Mov Disord movement disorders multiple system atrophy muscle mutations myoclonus neurodegenerative Neurol Neurosurg Psychiatry Neurology Neurosci normal nucleus onset orthostatic parkin Parkinson's disease parkinsonian pathology pathways patients with PD PD patients phenotype PINK1 placebo prevalence progressive supranuclear palsy proteasome protein rasagiline receptor reported response risk role selegiline SNpc stimulation striatal striatum Study Group substantia nigra symptoms therapy tics tion Tourette syndrome Tourette's treatment trial ubiquitin Wilson's disease